New cancer injection tested in hopeful fight against advanced head & neck tumors
NCT ID NCT04220866
Summary
This study tested whether adding a new drug (MK-1454) directly into tumors, alongside a standard immunotherapy drug (pembrolizumab), works better than the standard drug alone for advanced head and neck cancer. It involved 18 adults whose cancer had spread or returned and could not be removed by surgery. The goal was to see if the combination could better shrink tumors and control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allgemeines Krankenhaus der Stadt Wien ( Site 0049)
Vienna/Wien, Vienna, 1090, Austria
-
Asan Medical Center ( Site 0104)
Seoul, 05505, South Korea
-
Calvary Central Districts Hospital ( Site 0042)
Elizabeth Vale, South Australia, 5112, Australia
-
Centre Antoine Lacassagne ( Site 0070)
Nice, Alpes-Maritimes, 06189, France
-
Centre Leon Berard ( Site 0072)
Lyon, Auvergne, 69373, France
-
Centre Oscar Lambret ( Site 0071)
Lille, Nord, 59000, France
-
Centro Regional Integrado de Oncologia ( Site 0062)
Fortaleza, Ceará, 60336-232, Brazil
-
Chaim Sheba Medical Center ( Site 0076)
Ramat Gan, Tel Aviv, 5265601, Israel
-
Chris OBrien Lifehouse ( Site 0040)
Camperdown, New South Wales, 2050, Australia
-
Gustave Roussy ( Site 0068)
Villejuif, Val-de-Marne, 94800, France
-
H.U. Vall de Hebron ( Site 0112)
Barcelona, 08035, Spain
-
Hadassah Medical Center. Ein Kerem ( Site 0078)
Jerusalem, 9112001, Israel
-
Haukeland Universitetssykehus, Klinisk forskningspost voksne ( Site 0086)
Bergen, Hordaland, 5021, Norway
-
Henry Ford Hospital ( Site 0012)
Detroit, Michigan, 48202, United States
-
Hospital Clinico de Barcelona ( Site 0116)
Barcelona, 08036, Spain
-
Hospital Universitario Ramon y Cajal ( Site 0115)
Madrid, 28034, Spain
-
Hospital Universitario Virgen de la Victoria ( Site 0114)
Málaga, 29010, Spain
-
Hospital de Caridade de Ijui ( Site 0061)
Ijuí, Rio Grande do Sul, 98700-000, Brazil
-
Huntsman Cancer Institute ( Site 0004)
Salt Lake City, Utah, 84112, United States
-
IUCT - Oncopole ( Site 0069)
Toulouse, Haute-Garonne, 31059, France
-
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0058)
São Paulo, 01246-000, Brazil
-
Monash Health-Monash Medical Centre ( Site 0041)
Clayton, Victoria, 3168, Australia
-
Ordensklinikum Linz Gmbh - Barmherzige Schwestern ( Site 0051)
Linz, Upper Austria, 4010, Austria
-
Oslo Universitetssykehus Radiumhospitalet ( Site 0085)
Oslo, 0379, Norway
-
Rambam Medical Center ( Site 0077)
Haifa, 3109601, Israel
-
Real e Benemerita Associacao Portuguesa de Beneficencia ( Site 0064)
São Paulo, 01321-001, Brazil
-
Royal Marsden Hospital Sutton-Surrey ( Site 0032)
Sutton, Surrey, SM2 5PT, United Kingdom
-
Royal Marsden NHS Foundation Trust ( Site 0031)
London, London, City of, SW3 6JJ, United Kingdom
-
SCRI-CCCIT GesmbH ( Site 0050)
Salzburg, 5020, Austria
-
Sanford Cancer Center Oncology Clinic ( Site 0014)
Sioux Falls, South Dakota, 57104, United States
-
Severance Hospital ( Site 0103)
Seoul, 03722, South Korea
-
UCLA Hematology & Oncology ( Site 0005)
Los Angeles, California, 90095, United States
-
University of California at San Francisco ( Site 0006)
San Francisco, California, 94158, United States
-
Washington University ( Site 0021)
St Louis, Missouri, 63110, United States
Conditions
Explore the condition pages connected to this study.